Roche touts CHMP nod for Hemlibra; Alder raises $200M for migraine drug launch
→ Roche’s $RHHBY Hemlibra has just scored a positive opinion from CHMP, as it continues to tout the hemophilia drug as a potential blockbuster. The committee, whose recommendations are usually adopted by the European Commission, gave a thumbs up for Hemlibra’s prophylaxis of bleeding episodes in hemophilia A patients with factor VIII inhibitors of all age groups. The expected approval puts additional pressure on Shire, which bet big to establish itself in the hemophilia arena.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
